



ABN 53 075 582 740

ASX ANNOUNCEMENT
18 November 2015

Bionomics Limited (ASX:BNO, OTCQX: BNOEF) hereby gives notice to the Australian Securities Exchange ("ASX") that shareholders of the company passed all resolutions considered before the Annual General Meeting today.

The Notice of Annual General Meeting and accompanying documents were lodged with ASX on 16 October 2015.

This notice is given in accordance with ASX Listing rule 3.13.2 and section 251AA of the Corporations Act 2001.

| Resolution Number | Resolutions | Result | Proxy Votes | | | |
|-------------------|--|---------------------------------------|-------------|------------|------------|--------------------|
| | | | For | Against | Abstain | Proxy's discretion |
| 1 | Adoption of Remuneration Report | Passed unanimously on a show of hands | 160,676,934 | 5,127,609 | 1,370,522 | 2,893,607 |
| 2 | Re-election of Non-Executive Director – Mr Graeme Kaufman | Passed unanimously on a show of hands | 165,361,333 | 1,573,979 | 517,000 | 2,859,607 |
| 3 | Election of Non- Executive Director Dr Alan W. Dunton | Passed unanimously on a show of hands | 166,510,598 | 419,881 | 519,333 | 2,862,107 |
| 4 | Approval of Issue of Share Options to Dr Deborah Rathjen for Y/E 30 June 2015 | Passed unanimously on a show of hands | 139,521,869 | 5,353,127 | 22,420,556 | 2,849,669 |
| 5. | Approval of Issue of Share Options to Dr Alan W. Dunton | Passed unanimously on a show of hands | 133,688,558 | 32,846,668 | 760,326 | 2,849,669 |
| 6. | Ratification and approval of previous issue and allotment of shares to Merck Sharp & Dohme Corp. | Passed unanimously on a show of hands | 144,561,193 | 633,389 | 529,500 | 2,928,607 |

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+61 8 8354 6101
drathjen@bionomics.com.au

Mr Jack Moschakis
Legal Counsel & Company Secretary
+61 8 8354 6181
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 is expected to enter clinical trials in the fourth quarter of 2015. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au